Backed by decades of dedication to improving people’s health, Almirall combines scientific rigour with a deep understanding of skin health to deliver effective, patient-focused solutions.
I am a
I am looking for...
We contribute to improving the lives of millions of people worldwide across more than 100 countries. We are fully dedicated to medical dermatology with a focus on science and innovation.
Stories from people living with skin conditions
1/5
Ivet
Psoriasis
''My mum, who has psoriasis, has helped me a lot.''
Fede
Actinic keratosis
"When I discovered that AK was caused by solar damage, I was scared."
Mireia
Atopic dermatitis
"Atopic dermatitis can really affect your mental health."
We put patients and their families at the heart of every decision, guided by our purpose to transform their lives and help them achieve healthier futures.
With decades of investment in R&D, we advance skin biology and innovate alongside experts worldwide to deliver real impact for patients and dermatologists.
As a family-owned company, we act with integrity and transparency, and we are committed to sustainability through our Act4Impact 2030 strategy and guided by a long-term vision that creates value for people and society.
Latest updates on Almirall’s research, partnerships, and initiatives, offering patients and healthcare professionals clear insights into innovations shaping the future of dermatology.
1/5
As Pride Month comes to a close, we are reminded that the conversation around diversity, inclusion, and belonging should continue every day of the year. At Almirall, we believe that understanding the full patient experience means looking beyond the condition itself and recognizing the unique perspectives and identities that shape each person's journey.
Almirall, S.A. (ALM) and Certest Biotec, S.L., through its pharmaceutical division Certest Pharma, today announced a strategic research collaboration and licensing agreement. Through the collaboration, the parties will jointly discover and clinically develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions.
Almirall, S.A. (ALM) and Certest Biotec, S.L., through its pharmaceutical division Certest Pharma, today announced a strategic research collaboration and licensing agreement. Through the collaboration, the parties will jointly discover and clinically develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions.
As Pride Month comes to a close, we are reminded that the conversation around diversity, inclusion, and belonging should continue every day of the year. At Almirall, we believe that understanding the full patient experience means looking beyond the condition itself and recognizing the unique perspectives and identities that shape each person's journey.
At Almirall, sustainability is a key part of how we create long-term value for patients, society, and the planet. We are proud to share that we have once again been included in the World’s Most Sustainable Companies 2026 ranking, compiled by TIME and Statista.
Acne is one of the most common skin conditions worldwide, affecting millions of people across all ages and backgrounds. Yet, its impact extends far beyond the visible symptoms, often influencing self-confidence, emotional well-being, and daily life.
At Almirall, improving the lives of patients goes hand in hand with protecting the environment we all share. This World Environment Day, we want to reinforce our commitment to taking decisive climate action on our path to becoming a net-zero emissions company by 2050.
